Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune globulin - LFB Biotechnologies

Next Previous
Drug Profile

Immune globulin - LFB Biotechnologies

Alternative Names: Clairyg; I10E; Iqymune

Latest Information Update: 06 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LFB Biotechnologies
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Polyethylene glycols; Serum globulins; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Autoimmune disorders; Immunodeficiency disorders
  • Phase III Chronic inflammatory demyelinating polyradiculoneuropathy; Motor neuron disease

Most Recent Events

  • 06 Jan 2023 Discontinued - Phase-III for Chronic inflammatory demyelinating polyradiculoneuropathy in Spain, Italy, France, Tunisia, Germany, Germany, United Kingdom, Turkey (IV)
  • 18 Sep 2020 No development reported - Phase-III for Chronic inflammatory demyelinating polyradiculoneuropathy in Germany, Turkey, Tunisia, France, Italy, Spain and United Kingdom (IV)
  • 29 Sep 2017 LFB Biotechnologies completes the phase III PRISM trial in Chronic inflammatory demyelinating polyradiculoneuropathy in Germany, Turkey, Tunisia, United Kingdom, France, Italy and Spain (IV) (EudraCT2013-005557-73) (NCT02293460)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top